<?xml version="1.0" encoding="UTF-8"?>
<p>Mahoney, Morel and collaborators [
 <xref rid="pntd.0006469.ref002" ref-type="bibr">2</xref>, 
 <xref rid="pntd.0006469.ref021" ref-type="bibr">21</xref>â€“
 <xref rid="pntd.0006469.ref024" ref-type="bibr">24</xref>] identified six determinants, or components, of health technology innovation: (i) Development and expansion of national health delivery systems, including an attractive, domestic, private-sector market for health products; (ii) Development of manufacturing capability for health products; (iii) The drug and vaccine regulatory system; (iv) The IP regulatory system; (v) Development of R&amp;D capability by the public and private sectors; (vi) Development of international trade systems for health products, including global procurement funds. Because these innovation components are dynamically linked, successfully developing and introducing new technologies requires concerted attention to each of the six components [
 <xref rid="pntd.0006469.ref022" ref-type="bibr">22</xref>, 
 <xref rid="pntd.0006469.ref023" ref-type="bibr">23</xref>]. Using this framework, Morel et al analyzed the progress of developing countries in innovation capability and identified three intermediate stages before reaching a similar development level of industrialized nations [
 <xref rid="pntd.0006469.ref002" ref-type="bibr">2</xref>].
</p>
